GRAIL, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
GRAIL reported Q3 2026 revenue of $37.5M (up 4% YoY), with Galleri test revenue of $37.3M (up 14% YoY) and test volume up 24% to 56,000+ tests. The FDA's Molecular and Clinical Genetics Panel voted favorably on the Galleri multi-cancer early detection test in September, with an FDA decision anticipated by early Q1 2027. However, the company posted a net loss of $103.6M (Q3) and adjusted EBITDA loss of $(92.6)M, with adjusted gross margin declining to 42% from 55% year-over-year; cash position stands at $788.7M as of September 30, 2026.
Why this rating
FDA advisory approval is regulatory milestone de-risking path to market; revenue growth and test volume momentum are material. However, deteriorating gross margins and accelerating operating losses moderate the positive signal relative to $1.9B market cap.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.